#Paul Ehrlich Institute

[mycstilleblog]

"Gefahren durch mRNA-Impfstoffe": Wissenschaftler fordern endlich Auskunft vom Paul-Ehrlich-Institut

Corona machte die mRNA-Technologie im Eiltempo markttauglich. Doch erforscht ist vieles nicht, Studien fördern immer mehr Probleme zutage. Trotzdem mauern die Behörden, darunter das deutsche Paul-Ehrlich-Institut. Ein Professorenteam lässt nicht locker und dringt auf Antworten. Von Susan Bonath Um die Corona-Impfstoffe ist es still geworden, die mRNA-Technologie scheint sich, zur Freude einiger…

[transgenderer]

do people know "magic bullet" in the context of medicine just refers to like. medicines modern people think of as working in the normal way medicine does:

The magic bullet is a scientific concept developed by the German Nobel laureate Paul Ehrlich in 1907.[1] While working at the Institute of Experimental Therapy (Institut f��r experimentelle Therapie), Ehrlich formed an idea that it could be possible to kill specific microbes (such as bacteria), which cause diseases in the body, without harming the body itself.

salvarsan, in 1909, is considered the first magic bullet. like. medicine that treats disease without significantly harming you is so recent. obviously not all of our medicine is like that but idk, it just blows me away i guess. i feel like people dont think of this as that huge or recent a change but its at least on the scale of like, transportation technology

[darkmaga-returns]

A Danish group published a statistical analysis in 2023 showing disproportionate adverse events for early Pfizer-BioNTech vaccines, which was met with criticism from Anders Hviid, a Professor of epidemiology, and later by Borja Somovilla del Saz, a 23-year-old computer science student.

Somovilla del Saz’s criticism was the most prominent as it was referenced by Pfizer-BioNTech and the Paul Ehrlich Institut (“PEI”).

An investigation into Somovilla del Saz’s background and writing style has revealed inconsistencies, suggesting the involvement of external parties, and his critiques of various papers on vaccine safety and other topics appear to be reactionary and strategically timed.

It seems Somovilla del Saz is a ghostwriter used by the pharmaceutical industry to deliver messages that align with their interests.

[walkingghotst]

Europe Clinical Trials Market Share, Size, Key Players, Trends, Competitive and Regional Forecast (2022-2028)

The Europe clinical trials market is expected to grow from US$ 15,739.35 million in 2022 to US$ 21,643.87 million by 2028. It is estimated to grow at a CAGR of 5.5% from 2022 to 2028.

Increasing Adoption and Outsourcing of Clinical Trials Fuels Europe Clinical Trials Market

The process of determining the safety and efficacy of novel medical interventions, including new pharmaceuticals, dietary modifications, or medical devices, relies heavily on clinical trials, particularly during the drug development pipeline. Information from the European Medicines Agency reveals that approximately 4,000 clinical trials receive authorization annually within the European Union (EU), with around 60% originating from the pharmaceutical industry. The growing prevalence of chronic diseases is creating an increased demand for the development of effective treatments, thereby contributing to the expansion of the clinical trials market across Europe.

Furthermore, the increasing sophistication of clinical trial protocols necessitates meticulous execution and comprehensive oversight within research-focused organizations. To mitigate the potential for errors arising from inadequate implementation or monitoring, these organizations are increasingly relying on the outsourcing of clinical trial operations to specialized contract research organizations (CROs) to ensure the successful development of their products.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/BMIRE00028989

Europe Clinical Trials Market Overview

The European clinical trials market is geographically divided into the UK, Germany, France, Italy, Spain, and the remaining European countries. The anticipated rise in the initiation of clinical trials aimed at evaluating novel therapeutic compounds and supporting the launch of innovative healthcare solutions by various companies is projected to significantly drive market growth throughout Europe during the forecast period.

Within Germany, a substantial number of clinical trials are focused on understanding and treating conditions such as various forms of cancer, illnesses affecting the heart and blood vessels, disorders of the brain and nervous system, and infectious diseases. The nation's well-established infrastructure in sectors like transportation, communication technology, energy resources, and public services provides a solid foundation for the conduct of clinical research. Additionally, Germany has a large and accessible patient pool coupled with a strong commitment to high standards of healthcare. To further promote academic clinical research endeavors, centralized coordinating entities for clinical trials have been established through a dedicated funding program overseen by the Federal Ministry of Education and Research. The regulatory approval of clinical trials in Germany is handled by either the Federal Institute for Drugs and Medical Devices (BfArM) or the Paul-Ehrlich Institute (PEI), depending on the specific medicinal product being investigated. Consequently, Germany offers well-defined, dependable, and transparent regulatory pathways for clinical trial authorization, often characterized by relatively efficient study start-up timelines.

Europe Clinical Trials Market Segmentation

Europe Clinical Trials Market: By Study Design

Interventional

Observational

Expanded Access

Europe Clinical Trials Market: By Phase

Phase I

Phase II

Phase III

Phase IV

Europe Clinical Trials Market: By Indication

Autoimmune/Inflammation

Pain Management

Oncology

CNS Condition

Diabetes

Obesity

Cardiovascular

Europe Clinical Trials Market: Regions and Countries Covered     

Europe

UK

Germany

France

Russia

Italy

Rest of Europe

Europe Clinical Trials Market: Market leaders and key company profiles

Charles River Laboratories InternationalInc

ICON Plc

IQVIA Holdings Inc

IXICO Plc

Laboratory Corp of America Holdings

Parexel International Corp

SGS SA

Syneos Health Inc

Thermo Fisher Scientific Inc

WuXi AppTec Co Ltd

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

[nursingwriter]

Birth Control and Population According to Paul Ehrlich cited in the article "Too Many People," population issues in underdeveloped countries (UDCs) encompass rapid growth rates, birth rates vastly exceeding the death rate because of high percentages of young people, inadequate living standards, and serious problems with high urban concentrations. The consequences include resource depletion, ecosystem destruction, mass starvation, and a further deterioration of living stands. And, although not directly articulated, Ehrlich hits at political instability because rising expectations based on the knowledge of affluence in overdeveloped countries (ODCs) can't be realized. The conclusion Ehrlich reaches is that the overpopulation crisis justifies the imposition of mandatory birth control measures in UDCs that will result in zero population growth. While this view may initially seem undemocratic in nature, the reality is that his proposal is the only way to cope with the situation. To illustrate this point, this paper explores questions related to the mandatory birth control measures and provides answers that affirm the validity of them. So, is it fair to just target UDCs? The answer has to be yes because they are the ones with the largest problem. As Ehrlich explains, double times for populations in the UDCs range around twenty to thirty-five years. In contrast, doubling times for the populations of the ODCs tend to be dramatically higher, in the fifty to as much as two hundred year range. To put this in perspective, five developing countries today are responsible for more than fifty percent of the world's increase in population: India, China, Indonesia, Pakistan, and Nigeria. Simply put, it makes sense to target the problem where the problem is occurring. Most ODCs can adequately nourish their population; most UDCs cannot. Economic inequality is unfortunate, but it is a reality for which a solution must be applied to. Why can't we simply raise the living standards of UDCs and preserve procreation as a basic human right? While it's true that as industrialization progressed in ODCs, the number of children decreased, there's no hard evidence that economics was the main driver of the decrease in family size or, at the least, surely not the only driver. Ehrlich acknowledges that certain economic factors such as reduced reliance on child labor and the expense to raise and educate children may have played a part in birth reduction in maturing ODCs, but concludes that there may have been a reduction in the desire to have lots of children. However, the author does a poor job of describing factors that cause people to have many children and his argument could have been greatly strengthened by drawing in non-economic considerations such as cultural, social and religious reasons. For example, raising the standard of living may not overcome belief systems that value a woman by how many children she has or that encourage early marriages that lead to larger than average families. Shouldn't we tackle the problem of overpopulation from a consumption perspective, given that ODCs are the ones that consume a disproportionate amount of the world's resources and are the major polluters? This utilitarian ideal sounds great, but it's not realistic. The "Haves" will continue to consume more than their share because they can afford to do so. It's a basic economic tenet that the most relevant determinant of consumption is income. Certainly, a goal should be the wise use of resources and environmentally sound policies, but conservation alone can't solve the world's overpopulation problems. Further, it's entirely possible to consum less resources as is the case with UDCs, but to still generate a disproportionate amount of pollution and resource waste. Costlier environmental conservation may increasingly become the purview of ODCs that are in a better economic position to institute and follow conservation policies and regulations. Isn't it immoral to take away procreation rights? The answer to this is obviously a highly subjective one. It's only fair to concede that this is a difficult decision that does place constraints on what ideally should be basic human rights. But, the immorality of continued overpopulation outweighs the negatives of enforcing birth control. In the case of overpopulation, individual rights come at the expense of society. Watching children starve to death because they don't have enough to eat or witnessing the impacts of global warming on our environment are more painful than telling people they can't have more children. And, taking away procreation rights isn't exactly a fair characterization of mandatory birth control. Couples would still be allowed to have some number of acceptable children, they just wouldn't be allowed to have more than they and the world's resources can support. When considering the mandatory birth control issue, there is one final question that needs to be asked. What is the real alternative to this proposal? Ehrlich eloquently puts the answer to this question in black and white when he says, "Demographically, the whole problem is quite simple. A population will continue to grow as long as the birth rate exceeds the death rate-if immigration and migration are not occurring." This implies that overpopulation must be controlled either on the birth side or the death side. As unappealing as forced birth control sounds, it's unarguable a better choice than mass extermination. A third option could be added, the development of technology that will eliminate the problems associated with overpopulation by increasing the world's food supply, producing alternatives to natural resources and limiting pollution caused by people and businesses. However, there are two problems with this proposition. First, there's the real danger demand for technology will continue to outpace its supply. Secondly, UDCs do not have the resources or financial backing to develop or purchase emerging technologies that will help them solve their problems. In time, technology may hold more promise, but the urgent nature of problems the world is facing call for solutions that are available today. Doing nothing and betting on the future is a risky strategy. In summary, the imposition of mandatory birth control measures in UDCs that will result in zero population growth is absolutely justified. Overpopulation in UDCs is out of control and its consequences are devastating. Trying to focus on any area other than population growth in UDCs will only prove futile. Mandatory birth control does make a tradeoff between individual rights and social rights. It's a difficult decision, but the only real alternative. Consumption can't be easily controlled. Options such as death control are even more unacceptable and technology cannot be counted on to solve this problem in the foreseeable future. For all these reasons, mandatory population control policies must move forward as quickly as possible. Goldfarb, "Too Many People." "Population Dynamics By Country, Religion, or Ethnicity." Available: http://www.overpopulation.org/culture.html (Accessed 20 May 2005). Goldfarb, "Too Many People." Read the full article

[fabiansteinhauer]

Vor der Ikonologie

1.

Bevor Panofsky (oder wie Onkel Bazon schreibt: PanOfSky) etwas die Ikonologie gerufen (he called it), genannt oder bezeichnet hat, hat das Aby Warburg getan, nämlich in seiner Dissertation und in minoren Schreiben zur Dissertation, also auf Zetteln und in Notizen. Vor Gombrich, den Manderson hier mit Panofsky nennt (ruft und zum Ikonologen beruft) war schon Warburg und dazwischen war ein Wind, damit ein Sturm. Edgar Wind schreibt eine Rezension zu Gombrichs Biographie, die bestimmt nicht der Anlaß war, dass Wind dann zur Persona non grata im Insitut wurde. Aber er lieferte mit dieser Rezension den Leuten eine Ausrede dafür, dass er das jetzt sei. Die Rezension, die Wind zum Text des Direktors schrieb, was unerbittlich, da konnte man dem Wind gut in die Schuhe schieben, Schuld am Zerwürfnis zu haben. Georges Didi-Huberman hat aus Zusammenhängen und Konflikten dieser geschichte eine große Sache, eine große Geschichte gemacht (in: Das Nachleben der Bilder). So etwas besteht aus kleinen Dingen und kleinen Sachen, selbst Großzügigkeit besteht aus vielen kleinen Zügen.

2.

Egal mit welchem Maß: Das Projekt zu Warburgs Staatstafeln gilt dem, was 'vor dem Hintergrund' ist, also dem, was Desmond Manderson hier (aus-)spart, wenn er am Anfang von einem Background spricht, also ab der ein Anfang wäre. Die Ikonlogie vor Panofsky und vor Gombrich, die ist Gegenstand von Warburgs Staatstafeln. Was Warburg Ikonologie nennt, ist nicht das, was Panofsky Ikonologie nennt und nicht das, was Gombrich Ikonologie nennt. Das ist trivial zu sagen, aber nicht trivial zu entfalten.

Soll man Partei ergreifen? Ehrlich gesagt zieht es mich zum Wind, den ich für den anregensten, den wildesten derer halte, die bei Warburg auftauchten und etwas aus seinem hohen Berufsbezeichnungsverbrauch nutzen sollten, um wenigstens einen, nur einen einzigen Beruf zu erhalten, mindestens einmal berufen zu werden. Gertude Bing und Fritz Saxl hatten ihren Beruf gefunden, die laufen außer Konkurrenz, auch Ernst Cassirer. Der fantastische Paul Ruben (der mit Warburg einen hypnotisch fiebrigen oder manischen, euophorischen Briefverkehr führt, in dem beide wiederholt voll einsteigen auf das, was der andere schreibt) hat nie seinen Platz gefunden, musste immer weiter bitten, auch der läuft außer Konkurrenz, leider so, dass man das in der Literatur ein Schattendasein nennt, man kann vielleicht sogar von Verkümmern und dann Verrecken sprechen, müsste zuvor aber Björn Biester fragen, der Paul Ruben ein Buch gewidment hat.

Panofsky, Gombrich, Wind: irgendwann haben auch die einen Beruf gefunden, aber in der Zeit in der das noch nicht soweit war und die drei konkrurrierten und rivalisierten, da sticht Edgar Wind heraus, mit Schärfe, Mut, Witz, praktischem Geschick, Engagement und mutual aid, also mit Anarchie. Ich sehe in Wind denjenigen Erben Warburgs, der er in einer Geschichte hätte sein sollen, in der es keinen Shakespeare braucht. Wäre Wind gleich der Erbe geworden, dann kann man sich die insoweit die Lektüre Shakespeares sparen, zumindest alle Passagen, in denen es um das Erben geht. Das geschah aber nicht. Weder gleich noch irgendwann wurde Edgar Wind zum Erben Aby Warburgs. Hat Edgard Wind nach Warburgs Tod die Direktion des Institutes auch offiziel und abgesichert übernommen (die Leitung und Führung hat er zuerst, wenn auch informell und ungesichert übernommen), dann wäre es eine Uchronie (den ereignet hat sich diese Geschichte nicht). Das wäre aber keine Utopie, denn ohne Shakespeare würde auch was fehlen. Und Wind als Erbe: das wird dem Anarchisten vermutlich auch nicht gepasst haben.

[global-research-report]

Europe Blood Screening Market: Key Drivers, Challenges, and Forecasts for 2025

The Europe blood screening market size is expected to reach USD 1,954.8 million by 2030, registering a CAGR of 11.2% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing number of blood transfusion processes performed along with stringent regulations in Europe mandating screening tests, such as NAT for testing HIV, HBV, and HCV, is contributing to the market growth.

Moreover, growth in the overall number of complex surgeries that require a large amount of blood and blood products along with rising cases of road accidents is expected to drive the market further. Additionally, import of products through contract agreements and development in the product technology by manufacturers of blood screening reagents and instruments are contributing to market expansion in the region.

For example, DiaSystem Scandinavia AB signed a distribution agreement with SNIBE, an Asian immunology test producer that focuses on immunoassay analyzers based on CLIA technology. DiaSystem specializes in the production and supply of reagents used in chemistry and immunoturbidimetry. This agreement has provided the former company with automated chemiluminescence instrument delivering a complete analytical system in areas, such as thyroid, renal function, hepatitis, and hepatic fibrosis.

Europe Blood Screening Market Report Highlights

NAAT led the technology segment in 2022 owing to a regulatory obligation for mandatory NAAT screening for all blood donations.

On the basis of product, reagents led the Europe blood screening market in 2022

Germany held a majority of the market share in 2022 due to large number of blood donors.

Moreover, stringent regulations in the country for screening of donations also contributed to its growth. The Paul-Ehrlich-Institut, a medical regulatory body in Germany, mandates NAT testing for HCV and HIV for all blood donations.

Get Sample Copy of Europe Blood Screening Market

Europe Blood Screening Market Segmentation

Grand View Research has segmented the Europe blood screening market based on product, technology, and region:

Europe Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Europe Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test

ELISA

Chemiluminescence Immunoassay

Next Generation Sequencing

Western Blotting

Europe Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Key Players Europe Blood Screening Market

Danaher Corporation

Beckman Coulter, Inc.

Abbott Laboratories

Thermo Fisher Scientific Inc.

Becton, Dickinson and Company

Grifols

Ortho Clinical Diagnostics

Hoffmann-La Roche Ltd.

Bio-Rad Laboratories, Inc.

Siemens AG

Order a free sample PDF of the Europe Blood Screening Market Intelligence Study, published by Grand View Research.

[korrektheiten]

Kardiologe fordert strafrechtliche Ermittlungen gegen Paul-Ehrlich-Institut

Multipolar: »Mediziner: PEI hätte vor Gefahren der mRNA-Technologie warnen müssen / Kardiologe Jörg-Heiner Möller geht von mindestens einer halben Million Opfern der Corona-Impfstoffe aus / Impfschäden durch Spike-Proteine, Nano-Partikel und Verunreinigungen http://dlvr.it/TJBtQd «

[omg-erika]

Flu vaccination against coronavirus?

by Dr.Harald Wiesendanger– Klartext What the mainstream media is hiding The rampant fear of a coronavirus epidemic offers Federal Health Minister Jens Spahn another opportunity to live up to his reputation as a pharmaceutical lobbyist. While experts unanimously agree that a suitable vaccine will not be developed until the second half of the year at the earliest, at least the trained banker has…

[fuzzycashstudentangel]

Fast eine Million Verdachtsfälle: Chemie-Professoren kritisieren Paul-Ehrlich-Institut -

[tilos-tagebuch]

🇩🇪 Impfschäden: Wurden Opfer mit der Verjährung ausgetrickst?

Ende des Jahres lief die Klagefrist für die meisten Corona-Impfgeschädigten ab. Kurz davor stellte das Paul-Ehrlich-Institut klammheimlich eine Liste von fast einer Million Impfnebenwirkungen auf seine Webseite.

#deutschland #pei #corona #impfschäden

Source: https://www.0815-info.news/Web_Links-Wurden-die-Opfer-von-Impfschaeden-bei-der-Verjaehrung-ausgetrickst-visit-11598.html

[darkmaga-returns]

Are the Global Elites Over Population Control?

by Brad Pearce | Oct 21, 2024

It is widely believed among libertarians, and really everyone of anti-globalist sentiment, that there is a high-level global depopulation conspiracy. This belief is perhaps best summed up with the pithy phrase, “You are the carbon they want to reduce.” Bill Clinton recently acknowledged that he believes immigration is necessary for economic growth because our country has below-replacement fertility levels. While the global elites have given us many reasons to believe that they want depopulation, this is largely the residue of a panic about population growth from the 1960’s through 1980’s where many believed famine was imminent and ignored the vast increases in calorie production that accompanied the advent of modern industrial farming. Now, public policies across the developed world all demonstrate that governments are proactively, and unsuccessfully, trying to to increase birth rates in ways that are amenable to the public. In short, when it comes to population growth, the Very Serious People got what they thought they wanted but had never considered the impact of plummeting birthrates.

The population growth panic was started in earnest by the infamous book “The Population Bomb” by Paul Ehrlich which was released in 1968, though popular concern about overpopulation dates back to Malthus. A dystopian overpopulated future became a common trope in science fiction and was just one of many panics that academics and globalists have pushed on the world while selling panic as responsible planning. For one amusing example, the film Soylent Green is set in 2022 and though they were close to accurately predicting the 2022 population (7 billion in the movie, compared to 8 billion in real life) in the film that population level lead to the government feeding the public through stealth cannibalism. In real life, in 2022 Americans were suffering from obesity while wasting enormous amounts of food daily, and global extreme poverty had continuously gone down (not counting a rebound due to destructive COVID policies.) Despite that, for decades demographers have predicted the global population would peak in the 21st century, perpetually growing populations remain in the popular imagination.

The UN and various globalist oligarch organizations perpetuated overpopulation panic and tried to decrease birth rates, saying a variety of zany things about the need for much lower populations and proposing drastic actions. The invention of hormonal birth control and the legalization of abortion were primarily framed as serving the purpose of liberating women and allowing them to progress in the work force, but it was never hidden that the government desired to get birth rates down. The most famous and coercive example of population control policies being implemented was China’s “One Child Policy,” which was criticized by many, but widely praised by big international organizations and think tanks. Few considered the obvious problems that would impact a society where the average married couple had only one child but four elderly parents to take care of without the assistance of other siblings.

[trumpnewsdeutschland]

Warum hat das korrupte #PEI beim Bekanntwerden der Todesfälle und Nebenwirkungen durch die mRNA-#Biowaffe niemanden gewarnt?

Wer kann diesen Chemieprofessoren ihre Frage beantworten?

https://www.berliner-zeitung.de/gesundheit-oekologie/chemie-professoren-fragen-paul-ehrlich-institut-warum-haben-sie-nicht-gewarnt-li.2283637

#ploetzlichundunerwartet #Giftspritze #VerbrechenGegenDieMenschheit